Copy number alterations in papillary thyroid carcinomas: does loss of SESN2 have a role in age-related different prognoses?
Almeida, Deise Cibele N. de
Souza, Michel Platini Caldas de
Amorim, Carolina Koury Nassar
Maués, Jersey Heitor da Silva
Sagica, Fernanda do Espirito Santo
Moreira-Nunes, Caroline Aquino
Oliveria, Edivaldo Herculano Corrêa de
Background/Aim: Thyroid cancer is the only tumor in which age is an important prognostic factor. In papillary thyroid carcinomas (PTC), 45 years of age seems to be a key point that divides adult patients into two groups, with different clinical features. The aim of the study was to perform a microarray-based analysis in two groups of patients (<45 and ≥45 years old), in order to verify the occurrence of specific copy number alterations (CNAs) that could be associated to different patient behaviors associated with age. Patients and Methods: In order to search and compare genomic alterations that may be related to age, we evaluated the occurrence of CNAs in the genome of 24 PTC samples, divided in two groups (<45 and ≥45 years old). Results: We identified only one region showing a statistically significant difference between the groups (p=0.00357): a deletion of approximately 537 kps in 1p35.3., which was more frequent in patients aged 45 years or older. This is the region where, among others, the gene SESN2 is located, which is activated under oxidative stress and plays an antioxidant role, in addition to protecting the genetic material from damage generated by reactive oxygen species (ROS). Conclusion: This is the first time that a CNA involving the deletion of the SESN2 gene is associated with papillary thyroid carcinomas, particularly in patients aged 45 years and older, indicating that this deletion would lead to a more malignant and prominent tumoral behavior associated to a worst prognosis.
xmlui.dri2xhtml.METS-1.0.item-citationALMEIDA, Deise Cibele N. de et al. Copy number alterations in papillary thyroid carcinomas: does loss of SESN2 have a role in age-related different prognoses?. Cancer Genomics and Proteomics, v. 17, n. 5, p. 643-648, Sept./Oct. 2020.
xmlui.dri2xhtml.METS-1.0.item-decsPrimaryNeoplasias / diagnóstico
Neoplasias da Glândula Tireoide / diagnóstico
Câncer Papilífero da Tireoide
Estresse Oxidativo / genética
Idoso / fisiologia